Cargando…

Effects of berberine on pharmacokinetics of midazolam and rhodamine 123 in rats in vivo

AIM: To evaluate whether berberine hydrochloride (BBR) could modify the pharmacokinetic profiles of midazolam (MDZ), a substrate of CYP3A, and rhodamine 123 (Rh123), a substrate of P-glycolprotein (P-gp), in male rats. METHODS: The rats were given with varied does of BBR or 75 mg/kg ketoconazole as...

Descripción completa

Detalles Bibliográficos
Autores principales: Xin, Hua-Wen, Tang, Xia, Ouyang, Meng, Zhong, Jian-Xun, Li, Wei-Liang
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer International Publishing 2016
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4811842/
https://www.ncbi.nlm.nih.gov/pubmed/27066387
http://dx.doi.org/10.1186/s40064-016-2013-z
_version_ 1782424027364589568
author Xin, Hua-Wen
Tang, Xia
Ouyang, Meng
Zhong, Jian-Xun
Li, Wei-Liang
author_facet Xin, Hua-Wen
Tang, Xia
Ouyang, Meng
Zhong, Jian-Xun
Li, Wei-Liang
author_sort Xin, Hua-Wen
collection PubMed
description AIM: To evaluate whether berberine hydrochloride (BBR) could modify the pharmacokinetic profiles of midazolam (MDZ), a substrate of CYP3A, and rhodamine 123 (Rh123), a substrate of P-glycolprotein (P-gp), in male rats. METHODS: The rats were given with varied does of BBR or 75 mg/kg ketoconazole as a positive control for 10 days by intragastric administration. Single-pass duodenum perfusion of 20 mg/kg MDZ and inguinal artery canulated rats were used in the study. Plasma concentrations of MDZ and 1′-hydroxymidazolam (1′-OH-MDZ) were analyzed by high performance liquid chromatography (HPLC). The rats were given with varied does of BBR or 4 mg/kg verapamil as a positive control for 10 days by intragastric administration. Blood was obtained from the caudal vein of rats after single-pass intragastric administration of 5 mg/kg Rh123. HPLC was used to analyze the plasma concentrations of Rh123. RESULTS: BBR produced similar results as the ketoconazole (positive control group) with a dose-dependent increase in the AUC((0−t)) and AUMC ((0−t)) of midazolam except at the dose of 50 mg/kg (p < 0.01). And BBR could significantly increase the peak plasma concentrations (C(max)) of MDZ (p < 0.01), but reduce the clearance rate (CL(z)) and the apparent volume of the distribution (V(z)) of MDZ (p < 0.05). The results also indicated that BBR had no significant impact on the half-life period (t(1/2)) and the time to reach peak concentration (t(max)). Meanwhile, BBR could dose-dependently decrease AUC((0−t)) and AUMC((0−t)) of 1′-OH-MDZ significantly (p < 0.05), and expedite the clearance rate of 1′-OH-MDZ while gaining its apparent volume of distribution (p < 0.05), but had no significant impact on t(1/2) and T(max). The result also showed that BBR, except at the dose of 50 mg/kg, and the positive verapamil group could significantly increase the AUC((0−t)) and AUC((0−∞)) of Rh123 (p < 0.001), meanwhile raise C(max) of Rh123 and shorten its V(z) inversely (p < 0.05). Additionally, pre-treatment with BBR had no significant influence with the half-life period of Rh123, while significantly reduced its clearance rate (p < 0.05). CONCLUSION: The metabolism of MDZ and Rh123 was controlled by BBR. The results were most likely due to the inhibition by BBR on CYP3A enzymes and P-gp transporter.
format Online
Article
Text
id pubmed-4811842
institution National Center for Biotechnology Information
language English
publishDate 2016
publisher Springer International Publishing
record_format MEDLINE/PubMed
spelling pubmed-48118422016-04-10 Effects of berberine on pharmacokinetics of midazolam and rhodamine 123 in rats in vivo Xin, Hua-Wen Tang, Xia Ouyang, Meng Zhong, Jian-Xun Li, Wei-Liang Springerplus Research AIM: To evaluate whether berberine hydrochloride (BBR) could modify the pharmacokinetic profiles of midazolam (MDZ), a substrate of CYP3A, and rhodamine 123 (Rh123), a substrate of P-glycolprotein (P-gp), in male rats. METHODS: The rats were given with varied does of BBR or 75 mg/kg ketoconazole as a positive control for 10 days by intragastric administration. Single-pass duodenum perfusion of 20 mg/kg MDZ and inguinal artery canulated rats were used in the study. Plasma concentrations of MDZ and 1′-hydroxymidazolam (1′-OH-MDZ) were analyzed by high performance liquid chromatography (HPLC). The rats were given with varied does of BBR or 4 mg/kg verapamil as a positive control for 10 days by intragastric administration. Blood was obtained from the caudal vein of rats after single-pass intragastric administration of 5 mg/kg Rh123. HPLC was used to analyze the plasma concentrations of Rh123. RESULTS: BBR produced similar results as the ketoconazole (positive control group) with a dose-dependent increase in the AUC((0−t)) and AUMC ((0−t)) of midazolam except at the dose of 50 mg/kg (p < 0.01). And BBR could significantly increase the peak plasma concentrations (C(max)) of MDZ (p < 0.01), but reduce the clearance rate (CL(z)) and the apparent volume of the distribution (V(z)) of MDZ (p < 0.05). The results also indicated that BBR had no significant impact on the half-life period (t(1/2)) and the time to reach peak concentration (t(max)). Meanwhile, BBR could dose-dependently decrease AUC((0−t)) and AUMC((0−t)) of 1′-OH-MDZ significantly (p < 0.05), and expedite the clearance rate of 1′-OH-MDZ while gaining its apparent volume of distribution (p < 0.05), but had no significant impact on t(1/2) and T(max). The result also showed that BBR, except at the dose of 50 mg/kg, and the positive verapamil group could significantly increase the AUC((0−t)) and AUC((0−∞)) of Rh123 (p < 0.001), meanwhile raise C(max) of Rh123 and shorten its V(z) inversely (p < 0.05). Additionally, pre-treatment with BBR had no significant influence with the half-life period of Rh123, while significantly reduced its clearance rate (p < 0.05). CONCLUSION: The metabolism of MDZ and Rh123 was controlled by BBR. The results were most likely due to the inhibition by BBR on CYP3A enzymes and P-gp transporter. Springer International Publishing 2016-03-29 /pmc/articles/PMC4811842/ /pubmed/27066387 http://dx.doi.org/10.1186/s40064-016-2013-z Text en © Xin et al. 2016 Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made.
spellingShingle Research
Xin, Hua-Wen
Tang, Xia
Ouyang, Meng
Zhong, Jian-Xun
Li, Wei-Liang
Effects of berberine on pharmacokinetics of midazolam and rhodamine 123 in rats in vivo
title Effects of berberine on pharmacokinetics of midazolam and rhodamine 123 in rats in vivo
title_full Effects of berberine on pharmacokinetics of midazolam and rhodamine 123 in rats in vivo
title_fullStr Effects of berberine on pharmacokinetics of midazolam and rhodamine 123 in rats in vivo
title_full_unstemmed Effects of berberine on pharmacokinetics of midazolam and rhodamine 123 in rats in vivo
title_short Effects of berberine on pharmacokinetics of midazolam and rhodamine 123 in rats in vivo
title_sort effects of berberine on pharmacokinetics of midazolam and rhodamine 123 in rats in vivo
topic Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4811842/
https://www.ncbi.nlm.nih.gov/pubmed/27066387
http://dx.doi.org/10.1186/s40064-016-2013-z
work_keys_str_mv AT xinhuawen effectsofberberineonpharmacokineticsofmidazolamandrhodamine123inratsinvivo
AT tangxia effectsofberberineonpharmacokineticsofmidazolamandrhodamine123inratsinvivo
AT ouyangmeng effectsofberberineonpharmacokineticsofmidazolamandrhodamine123inratsinvivo
AT zhongjianxun effectsofberberineonpharmacokineticsofmidazolamandrhodamine123inratsinvivo
AT liweiliang effectsofberberineonpharmacokineticsofmidazolamandrhodamine123inratsinvivo